Evidence map›Paper›PMID 39836706›Full record

ArticlePLoS pathogens2025

Assessing bnAb potency in the context of HIV-1 envelope conformational plasticity.

Caio Foulkes, Nikolas Friedrich, Branislav Ivan, Emanuel Stiegeler, Carsten Magnus, Daniel Schmidt, Umut Karakus, Jacqueline Weber, Huldrych F Günthard, Chloé Pasin and 2 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Caio FoulkesInstitute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
Nikolas FriedrichInstitute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.ORCID 0000-0003-0694-657X
Branislav IvanInstitute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
Emanuel StiegelerInstitute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
Carsten MagnusInstitute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
Daniel SchmidtInstitute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
Umut KarakusInstitute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
Jacqueline WeberInstitute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
Huldrych F GünthardInstitute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
Chloé PasinInstitute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
Peter RusertInstitute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
Alexandra TrkolaInstitute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.ORCID 0000-0003-1013-876X

Funding

SHCS research foundationSwiss National Science Foundation
6 · The paper itself

Abstract

For use in prevention and treatment, HIV-1 broadly neutralizing antibodies (bnAbs) have to overcome Env conformational heterogeneity of viral quasispecies and neutralize with constant high potency. Comparative analysis of neutralization data from the CATNAP database revealed a nuanced relationship between bnAb activity and Env conformational flexibility, with substantial epitope-specific variation of bnAb potency ranging from increased to decreased activity against open, neutralization-sensitive Env. To systematically investigate the impact of variability in Env conformation on bnAb potency we screened 126 JR-CSF point mutants for generalized neutralization sensitivity to weakly neutralizing antibodies (weak-nAbs) depending on trimer opening and plasma from people with chronic HIV-1 infection. 23 mutations resulted in a highly neutralization sensitive phenotype, which was associated with de-stabilization of the closed, prefusion conformation. Including 19 of these mutants into a Sensitivity Env mutant panel (SENSE-19), we classified bnAbs according to potency variations in response to trimer opening. To verify that these sensitivity patterns are independent of the in vitro assay system, replication-competent SENSE-19 mutant viruses were tested on primary CD4 T cells. While loss of potency on SENSE-19 was registered for bnAbs from several classes recognizing quaternary epitopes on pre-triggered Env, structural destabilization benefitted MPER bnAbs and other inhibitors known to have post-CD4 attachment neutralization activity. Importantly, for a subset of CD4bs bnAbs, and the interface bnAb PGT151, particularly low potency variation was noted, suggesting that Env conformational tolerance can be achieved but is not the rule. In summary, SENSE-19 screens revealed distinct tolerance levels to Env conformational intermediates between bnAbs that provide mechanistic insights in their function and broaden current neutralization breadth assessments.

Indexed as

Antibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV-1HIV AntibodiesHIV InfectionsEpitopesHumansNeutralization TestsProtein ConformationAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusEpitopesHIV Antibodies

Identifiers

PMID39836706
PMCPMC11774494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.